During the ClinTriCare company meeting on 21 and 22 September 2017, we invited an expert who shed light on what he described as the “Black box IMP”. The speaker is a pharmacist specializing in clinical pharmacy and for 20 years has been working for one of the largest research-based pharmaceutical companies in Germany. He specializes in pharmaceutical development of medicines and the supply of investigational medicinal products (IMP) for clinical trials.

This continuing education event featured a lot of interesting information about the challenges of the blinding of trial medication and was able to impart important background knowledge to the ClinTriCare staff about the IMP-related processes during the conduct of clinical trials.